RVNC - Revance stock climbs on positive Daxi data in facial line study

Revance Therapeutics ([[RVNC]] +6.7%) has announced positive efficacy and duration results from Phase 2 upper facial lines study, evaluating Daxibotulinumtoxin A for Injection in the combined treatment of glabellar lines, forehead lines and crow’s feet lines.The trial showed efficacy of none or mild wrinkle severity in at least 92% of subjects at week 4.Median time to return to baseline wrinkle severity was at least 33 weeks (7.6 months).Treatment with Daxibotulinumtoxin A for Injection was well tolerated across upper facial regionsRevance is currently awaiting a decision on the approval of Daxibotulinumtoxin A for Injection for the treatment of glabellar lines by FDA, pending a manufacturing site inspection, which was delayed due to Covid-19 travel restrictions.

For further details see:

Revance stock climbs on positive Daxi data in facial line study